Recruiting NCT06438445

Effects of Royal Jelly Supplementation in Chronic Kidney Disease

Trial Parameters

Condition Kidney Failure, Chronic

Sponsor Universidade Federal Fluminense

Study Type INTERVENTIONAL

Phase N/A

Enrollment 30

Sex ALL

Min Age 18 Years

Max Age 70 Years

Start Date 2024-07-30

Completion 2025-12-22

All Conditions

Kidney Failure, Chronic Oxidative Stress Hemodialysis

Interventions

Real JellyPlacebo

Brief Summary

The objective of this study is to evaluate the effects of royal jelly on inflammation and cellular senescence in patients with chronic kidney disease (CKD) on hemodialysis (HD).

Eligibility Criteria

Inclusion Criteria: * patients with CKD undergoing hemodialysis for more than 6 months * patients with arteriovenous fistula (AVF) as vascular access. Exclusion Criteria: * pregnant, * lactating, * smoker * patients using antibiotics and antioxidant supplements in the last three months * patients with autoimmune and infectious diseases, * patients with cancer, liver disease, and AIDS

Related Trials

NCT03573089

Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPH

View Trial →

NCT06438445

Effects of Royal Jelly Supplementation in Chronic Kidney Disease

View Trial →

NCT06660277

DIALysis With EXpanded Solute Removal

View Trial →

VIEW ON CLINICALTRIALS.GOV ↗ MORE KIDNEY FAILURE, CHRONIC TRIALS